Excision BioTherapeutics

Excision presented data on EBT-107 at the 2024 International HBV Meeting, highlighting its potential to increase Hepatitis B cure rates. Dr. Ryo Takeuchi emphasized: - Significant suppression of HBV sAg and eAg - Reduction of HBV DNA - Utilization of dual guide CRISPR editing with lipid nanoparticles Learn more: https://loom.ly/1IfiuqE #ExcisionBio #HBVResearch #GeneTherapy

Join us today at 2:30 pm CDT as Dr. Ryo Takeuchi, Senior Director of Genome Editing at Excision, presents on 'Development of multiplex gene editing therapy with paired guide RNAs for the cure of chronic hepatitis B' at the 2024 International HBV Meeting. Don’t miss this insightful session! Learn more: https://loom.ly/1IfiuqE #Excision #HepatitisB #GeneEditing #HBVMeeting2024 #CRISPR

We're pleased to announce that Dr. Ryo Takeuchi, Senior Director, Genome Editing at Excision, will be delivering an oral presentation at the 2024 International HBV Meeting. Join us on Saturday, September 14th at 2:30pm CDT to hear his insights on "Development of Multiplex Gene Editing Therapy with Paired Guide RNAs for the Cure of Chronic Hepatitis B." Read more: www.excision.bio #ExcisionBio #HepatitisB #GeneEditing #GeneTherapy #CRISPR #HBVMeeting2024 #EBT107

Today, Excision announced a new publication in Molecular Therapy Methods & Clinical Development on EBT-104 for HSV-1 keratitis treatment. • EBT-104 eliminated viral shedding in 92% of treated rabbits' eyes. •Our gene editing technology offers curative potential for corneal blindness in the US. • HSV keratitis affects 1.5 million globally each year, with 40,000 severe cases. 📍Read the full publication: https://lnkd.in/gmESfRJ2 #ExcisionBio #MolecularTherapy #HSV #CRISPR #GeneEditing

We're honored to have been awarded one of the 'Fierce 15' Biotech Companies of 2024 by Fierce Biotech. Our unique use of CRISPR/Cas gene editing has recently achieved in vivo proof-of-concept in combating Herpes Virus and Hepatitis B. These breakthroughs offer hope for addressing the root causes of the infections and related diseases including a leading cause of infectious blindness. Read more: https://loom.ly/1IfiuqE #Excision

We're excited to share that Excision BioTherapeutics has been mentioned in a recent article highlighting our Phase 1/2 trial of EBT-101 in HIV and promising preclinical results for herpes and hepatitis B. These findings underscore the potential of our CRISPR-based therapies. Read more: https://loom.ly/L8u-X08 #Excision

Celebrating a successful showcase at #ASGCT2024, Excision Biotherapeutics is proud to have shared our groundbreaking research at the event. We pushed the boundaries of gene therapy, leaving a lasting impact. #Excision #ExcisionBio

Today, Excision BioTherapeutics announced data from our Phase 1/2 Trial of EBT-101 in HIV and In Vivo Efficacy data in Herpes Virus and Hepatitis B. Read our press release: https://loom.ly/YxPaq_8 #Excision #Excisionbio

TODAY | Join Dr. Rachel Presti for an update on Excision Biotherapeutics’ HIV-1 clinical trial at #ASGCT2024! Discover the transformative potential of our gene editing technologies firsthand. Learn more: https://loom.ly/aLsEjFo #ExcisionBio #ASGCT #GeneEditing

Mark your calendars for tomorrow, May 10th! Excision Biotherapeutics is gearing up to present our latest advancements in gene editing at #ASGCT2024. Don't miss out on the opportunity to explore the forefront of biotechnology. Visit: https://loom.ly/aLsEjFo #ExcisionBio #ASGCT #Innovation